SyStemix Inc. of Palo Alto, Calif., appointed three seniorexecutives. Stephen G. Marcus and Sue Gilbert were named vicepresident of medical and regulatory issues and chief financialofficer, respectively. Didier Lanson was named vice presidentof European operations of SyStemix International, S.A.R.L.Marcus was director of oncology clinical research worldwideat Schering Plough Corp., Gilbert was vice president ofcorporate development for Syntex Corp., and Lanson waspresident and chief executive officer of Espace Vie S.A.
Cytel Corp. of San Diego named Karin Eastham vice president offinance and administration and chief financial officer. She wasvice president of fiance and administration of the PritskerCorp., a computer software company.
GenPharm International Inc. of Mountain View, Calif., namedDavid L. Winter president and chief operating officer forGenPharm U.S. He was senior R&D executive for the past 13years with Sandoz Pharmaceuticals.
Alteon Inc. of Northwale, N.J., named Jere E. Goyan senior vicepresident for research and development. He was a consultant toAlteon and a member of its scientific advisory board since1989, and is currently dean of the school of pharmacy at theUniversity of California in San Francisco.
MedChem Products Inc of Woburn, Mass.,. named Jonathan D.Donaldson chief executive officer. Donaldson will remainpresident, a title he has held since 1986.
Boston Pacific Medical Inc. named Peter J. Zahoruiko presidentand general manger of BP Malaysia, the Boston company'swholly owned manufacturing and distribution facility.Zahoruiko was general manager of Phase-R Corp.
Applied Immune Sciences Inc. of Menlo Park, Calif., namedAlton B. Kremer medical director for AIDS and cancer therapy.Kremer was director of clinical research at G.D. Searle & Co.
Applied Immune also elected Charles H. Blanchard to its boardof directors. Blanchard is group vice president of BaxterInternational Inc. and president and chief executive officer ofCaremark Inc., Baxter's home health care affiliate.
Gliatech Inc. of Cleveland named Michael J. Demchuk Jr. vicepresident and chief financial officer. He had been chieffinancial officer at Nova Pharmaceutical Corp.
Genelabs Technologies Inc. of Redwood City, Calif., named MikeAnderson controller. Anderson had been cost accountingmanager and general accounting manager with AppliedBiosystems Inc.
Baxter International Inc. of Deerfield, Ill., named George St.Laurent Jr. a director of the company. St. Laurent is chairmanand chief executive officer of Western Bank, the largestindependent bank in Oregon.
Interneuron Pharmaceuticals Inc. of Lexington, Mass., namedGlenn L. Cooper president and chief executive officer ofProgenitor Inc. Progenitor is a subsidiary of Interneuronformed to collaborate with Ohio University to isolate, growand genetically engineer yolk sac stem cells. Cooper wasexecutive vice president and chief operating officer of SphinxPharmaceuticals Corp.
MedClone Inc. of Los Angeles named Martin L. Lee director ofregulatory affairs and clinical programs. He was vice presidentfor regulatory affairs, quality assurance and clinical programsfor the technology and ventures division of Baxter HealthcareCorp.
ImmunoGen Inc. of Cambridge, Mass., named Dixie Esseltinedirector of oncology. She was associate director for clinicalresearch and development with Ortho-McNeil.
Creative BioMolecules Inc. of Hopkinton, Mass., named Brian H.Dovey to its board of directors. He is a general partner ofDomain Associates.
TheraTech Inc. of Salt Lake City named Raymond S. Varnackasvice president of manufacturing and Donald Mantle vicepresident of quality control/quality assurance Varnackas wasassociate director of technical services at Ciba-Geigy'spharmaceutical division for 25 years. Mantle was withSchering Laboratories.
Telor Ophthalmic Pharmaceuticals Inc. named Sophann Immanager of pharmaceutical development. She was director ofpharmaceutical development for Bausch &Lomb'spharmaceutical division.
Affinity Biotech Inc. named Nathan R. Tzodikov director ofanalytical services. The Boothwyn, Pa., company also namedFrederick M. Danziger and Geraldine A. Henwood to its board ofdirectors.
Future Medical Products Inc. of Hauppauge, N.Y., said BarryCohen will assist the company in establishing joint venturesand business alliances with major pharmaceutical companies,products development and marketing. Cohen was senior vicepresident of Merck & Co. Inc. and is considered the architect ofMerck's international business.
(c) 1997 American Health Consultants. All rights reserved.